These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30094493)

  • 1. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
    Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
    Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
    Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
    Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.
    Bartels S; Christgen M; Luft A; Persing S; Jödecke K; Lehmann U; Kreipe H
    Mod Pathol; 2018 Jan; 31(1):56-61. PubMed ID: 28799536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
    Ding Q; Chen H; Lim B; Damodaran S; Chen W; Tripathy D; Piha-Paul S; Luthra R; Meric-Bernstam F; Sahin AA
    Hum Pathol; 2019 Oct; 92():32-38. PubMed ID: 31351155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
    Djerroudi L; El Sabeh-Ayoun A; Benoist C; Pierron G; Masliah-Planchon J; Fuhrmann L; Kieffer Y; Carton M; Ramtohul T; Callens C; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
    Mod Pathol; 2024 May; 37(5):100463. PubMed ID: 38428737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
    Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
    J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
    Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
    J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
    Uchida S; Kojima T; Sugino T
    Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type.
    Monhollen L; Morrison C; Ademuyiwa FO; Chandrasekhar R; Khoury T
    Histopathology; 2012 Sep; 61(3):365-77. PubMed ID: 22486370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
    LeNoue-Newton ML; Chen SC; Stricker T; Hyman DM; Blauvelt N; Bedard PL; Meric-Bernstam F; Punglia RS; Schrag D; Lepisto EM; Andre F; Smyth L; Dogan S; Yu C; Wathoo C; Levy M; Eli LD; Xu F; Mann G; Lalani AS; Ye F; Micheel CM; Arnedos M
    Clin Cancer Res; 2022 May; 28(10):2118-2130. PubMed ID: 35190802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
    Yau TK; Sze H; Soong IS; Hioe F; Khoo US; Lee AW
    Hong Kong Med J; 2008 Apr; 14(2):130-5. PubMed ID: 18382020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.